


PRESS RELEASE



For More Information:

Company Contact:

Emilio Cordova
Chief Executive Officer
Phone: 312-235-3575
ecordova@samditech.com

SAMDITech, Inc Named a National Cancer Institute NExT Laboratory

CHICAGO, IL – June 2, 2016 -- **SAMDITech** has been named a specialized screening center for the National Cancer Institute's Experimental Therapeutics Program, or NExT. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. SAMDI Tech's label-free assay platform will be an important tool in the NExT pipeline for discovery of novel small molecules as inhibitors for next generation cancer targets.


The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. SAMDI Tech is participating in the consortium via a research subcontract from Leidos Biomedical Research, Inc., prime contractor at the national lab.

The Chemical Biology Consortium is the discovery engine for the NCI Experimental Therapeutics (NExT) Program working to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. SAMDI Tech's label-free assay platform will be an important tool in the NExT pipeline for discovery of novel small molecules as inhibitors for next generation cancer targets.

"We are excited to be part of the NCI NExT pipeline and to offer our label-free assay capabilities to the exciting targets in the program," said Michael Scholle, VP of Operations and Technology.

"SAMDITech continues to be at the forefront of cancer research and our partnership with the National Cancer Institute affirms our role as a leader in drug discovery research services. We look forward to a productive endeavor and providing services to NExT ." said Dr. Emilio Córdoba, CEO of SAMDI Tech.

PRESS RELEASE



For More Information:

Company Contact:

Emilio Cordova
Chief Executive Officer
Phone: 312-235-3575
ecordova@samditech.com

About SAMDI Tech, Inc:

SAMDITECH, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI's pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at www.samditech.com

About the Frederick National Laboratory for Cancer Research:

The Frederick National Laboratory for Cancer Research is a federal national laboratory sponsored by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). The Frederick National Lab collaborates with academic, commercial, nonprofit, and government researchers to address urgent problems in biomedical research consistent with NCI's mission. The national lab is government-owned, contractor-operated facility with Leidos Biomedical Research Inc., as its prime contractor.

About NCI NExT:

The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. The NExT Program is not a grant mechanism; applications with exceptional science cannot be accepted without a clear path to the clinic or potential benefit to patients. Awardees will not necessarily receive direct funding; rather, the NCI may allocate various contract and grant resources toward the implementation and development of submitted projects. The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration.